🟢 MRNA is trading 4.66% up today, extending a rally fueled by landmark flu and hantavirus vaccine data

MRNA is trading at $56.88 (+4.66%) as shares extend a rally triggered by positive clinical data for its flu and hantavirus vaccine candidates.

• The stock has gained approximately 24% since May 5, bucking broader market uncertainty and declining index futures stemming from U.S.-Iran tensions.
• Shares reached a premarket high of $58.20 following a strong performance on May 8, where the stock closed up 11.97% at $54.35.
• Moderna led premarket gainers according to GuruFocus, maintaining momentum from last week's landmark vaccine announcements.